Farletuzumab (FAR), farletuzumab clinical studies, are designed to investigate the safety and efficacy of farletuzumab in patients with folate receptor alpha (FRA) expressing tumors. FRA expressing tumors currently under investigation are platinum-sensitive epithelial ovarian cancer and nonsmall cell lung adenocarcinoma.

For more information regarding FAR studies, please click here http://www.ovarianstudies.com/ and http://www.ClinicalTrials.gov/.

The FAR-131 clinical research study is evaluating whether the investigational drug MORAb-003 (farletuzumab) is safe and effective when given in combination with carboplatin and taxane for women who have platinum-sensitive epithelial ovarian cancer that has relapsed within 6 to 24 months after first-line treatment with a platinum-containing chemotherapy regimen.

The goal of this research study is to learn whether farletuzumab can provide additive benefit to currently approved chemotherapeutic regimens.

FAR-131 study is actively recruiting patients in approximately 30 countries located within North-/Central-/South-American, Europe, and Asia/Pacific.  For more information regarding this clinical study Click here (ClinicalTrials.gov Identifier: NCT00849667 and http://www.ovarianstudies.com/) or call toll-free number 877-FAR-1311 (877-327-1311).

MORAb-003-002a is an extended Phase 2 efficacy study of farletuzumab in patients with platinum-sensitive epithelial ovarian cancer in first relapse.

The goal of this study is to continue farletuzumab therapy in progression-free patients who had succesfully completed combination and maintenance therapy in the Phase 2 study, MORAb-003-002.

For more information regarding this clinical study Click here (ClinicalTrials.gov Identifier: NCT01018563).

This Phase 1 study to test the safety, tolerability, and pharmacokinetics of farletuzumab in Japanese patients with folate receptor alpha (FRA)-expressing solid tumors is ongoing.

Additional objectives of this study are to investigate any dose-limiting toxicity and estimate the maximum tolerated dose (MTD) in Japanese patients.

For more information regarding this clinical study Click here (ClinicalTrials.gov Identifier: NCT01049061).

A Phase 1 safety study of farletuzumab, added to the chemotherapy regimen of carboplatin and pegylated liposomal doxorubicin (PLD) in patients with platinum-sensitive ovarian cancer that has relapsed after platinum-containing therapy.

The goal of this study is to evaluate whether combination therapy with farletuzumab, carboplatin, and PLD is safe.

For more information regarding this clinical study Click here (ClinicalTrials.gov Identifier: NCT01004380).

An Phase 2 study of farletuzumab in patients who are newly diagnosed with stage IV FRA‐expressing adenocarcinoma of the lung.

The goal of this study is to evaluate whether therapy with farletuzumab is effective and safe in combination with cisplatin/taxane, carboplatin/taxane or carboplatin/pemetrexed followed by farletuzumab monotherapy.

For more information regarding this clinical study Click here (ClinicalTrials.gov Identifier: NCT01218516).



For more information about farletuzumab, please click here.



The information contained herein is investigational and is not intended to make claims of safety or efficacy prior to approval by the FDA or other regulatory authorities. There is no guarantee that the agents described or their uses will be approved by the FDA or other regulatory authorities.